Clinical Practice Surveillance of the Use of Herceptin Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms HerSCin
- Sponsors Roche
- 01 Feb 2018 Planned end date changed from 1 Jul 2018 to 30 Sep 2018.
- 01 Feb 2018 Planned primary completion date changed from 1 Jul 2018 to 30 Sep 2018.
- 12 Sep 2017 Results of second planned interim analysis (n=420) at data cut-off (Nov 2016) presented at the 42nd European Society for Medical Oncology Congress